首页> 外文OA文献 >PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

【2h】

PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

机译：PD3-3-5：贝伐单抗（B）联合卡铂（C）和紫杉醇（P）联合治疗的老年晚期非小细胞肺癌（NSCLC）老年患者（pts）：东部合作肿瘤小组分析（ ECOG）4599研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Ramalingam Suresh S.; Dahlberg Suzanne E.; Langer Corey J.; Gray Robert; Belani Chandra P.; Brahmer Julie R.; Sandler Alan; Schiller Joan H.; Johnson David H.;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. [J] . Brahmer JR, Dahlberg SE, Gray RJ, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2011,第1期

机译：贝伐单抗治疗的预后性别差异：在东部合作肿瘤小组试验4599中分析接受或不接受贝伐单抗联合紫杉醇和卡铂治疗的晚期非小细胞肺癌患者。
2. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. [J] . Ramalingam SS, Dahlberg SE, Langer CJ, Journal of Clinical Oncology . 2008,第1期

机译：贝伐单抗联合卡铂和紫杉醇治疗的老年晚期非小细胞肺癌晚期患者的结局：东部合作肿瘤小组试验4599分析。
3. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) [J] . Hanna Nasser H., Dahlberg Suzanne E., Kolesar Jill M., Cancer: A Journal of the American Cancer Society . 2015,第13期

机译：三臂，卡铂和紫杉醇联合西妥昔单抗，西妥昔单抗或两者均用于不接受贝伐珠单抗治疗的晚期非小细胞肺癌（NSCLC）患者的2阶段随机研究：东方合作肿瘤小组（ECOG ）研究（E4508）
4. Does Sex Make a Difference in Survival of Patients Undergoing Resection for Early Stage Non-Small Cell Lung Cancer (NSCLC)? [C] . Steven J.Jubelirer, Nicole L.Varela, Christine A.Welch, 21st international conference on screening for lung cancer . 2009

机译：性别对早期非小细胞肺癌（NSCLC）切除患者的生存率有影响吗？
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-Small-Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 [O] . Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, -1

机译：贝伐单抗治疗结果的性差异：患有或不含Bevacizumab的晚期非小细胞肺癌患者的分析与紫杉醇和卡铂联合在东方合作肿瘤学群试验4599中
7. Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 [O] . Brahmer Julie R., Dahlberg Suzanne E., Gray Robert J., 2011

机译：贝伐单抗治疗结果的性别差异：东部合作肿瘤小组试验4599中接受或不接受贝伐单抗联合紫杉醇和卡铂治疗的晚期非小细胞肺癌患者的分析

PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

著录项

相似文献

相关主题

期刊订阅